One of our favorite pancreatic cancer researchers, Dr. Daniel Von Hoff of TGen in Arizona – together with researchers from the Virginia G Piper Cancer Center – is reporting encouraging clinical trials results for those with advanced pancreatic cancer treated with a combination of Abraxane plus gemcitabine. This MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study as chaired by Dr. Von Hoff is a part of a multi-center international investigation of 861 patients with results that are expected to be reported out in greater detail at the ASCO GI symposium in San Francisco in January 24-26, 2013. Dr. Von Hoff was a key researcher on the early development of gemcitabine.
Dale O’Brien, MD